Monte Rosa Therapeutics, Inc.

NasdaqGS:GLUE

Market Cap

USD 358.60 M

Share Price

USD 5.83

Avg Daily Volume

532,675

Change (1 day)

-1.85%

Change (1 year)

36.85%

Change (YTD)

-15.99%

Monte Rosa Therapeutics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2025: -1.33%

Monte Rosa Therapeutics, Inc. EBIT Margin is -1.33% for the Trailing 12 Months (TTM) ending March 31, 2025, a -99.91% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Monte Rosa Therapeutics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was -1,466.97%.
Key Data
Date EBIT Margin EBITDA Margin Net Income Margin EBT Margin